Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Royalty Pharma Plc (RPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RPRX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $43.27
1 Year Target Price $43.27
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.23% | Avg. Invested days 48 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 21.29B USD | Price to earnings Ratio 15.94 | 1Y Target Price 43.27 |
Price to earnings Ratio 15.94 | 1Y Target Price 43.27 | ||
Volume (30-day avg) 8 | Beta 0.54 | 52 Weeks Range 23.59 - 37.77 | Updated Date 08/15/2025 |
52 Weeks Range 23.59 - 37.77 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 2.36% | Basic EPS (TTM) 2.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When Before Market | Estimate 1.03 | Actual 1.14 |
Profitability
Profit Margin 44.28% | Operating Margin (TTM) 38.85% |
Management Effectiveness
Return on Assets (TTM) 6.49% | Return on Equity (TTM) 17.29% |
Valuation
Trailing PE 15.94 | Forward PE 12.09 | Enterprise Value 22293149325 | Price to Sales(TTM) 9.23 |
Enterprise Value 22293149325 | Price to Sales(TTM) 9.23 | ||
Enterprise Value to Revenue 9.67 | Enterprise Value to EBITDA 11.54 | Shares Outstanding 432292992 | Shares Floating 380076372 |
Shares Outstanding 432292992 | Shares Floating 380076372 | ||
Percent Insiders 8.73 | Percent Institutions 88.25 |
Upturn AI SWOT
Royalty Pharma Plc
Company Overview
History and Background
Royalty Pharma Plc was founded in 1996 and is headquartered in New York, NY. It's the largest buyer of pharmaceutical royalties and related assets, focusing on acquiring revenue-producing royalties rather than developing new drugs.
Core Business Areas
- Acquisition of Royalties: Acquires royalties and related interests associated with approved and marketed biopharmaceutical products, providing upfront capital to innovators in exchange for a stream of future revenue.
- Co-Funding Clinical Trials: Co-funds late-stage clinical trials in exchange for future royalties on successful drugs, providing capital to pharmaceutical companies.
Leadership and Structure
Pablo Legorreta is the founder and Chief Executive Officer. The company has a board of directors and a management team responsible for strategic decision-making and operations.
Top Products and Market Share
Key Offerings
- Tysabri: Royalty Pharma holds a royalty interest in Tysabri (natalizumab), a treatment for multiple sclerosis. Competitors include other MS drugs such as those from Biogen (BIIB) and Novartis (NVS). Revenue and market share data are confidential; Royalty Pharma's revenues are tied to the overall performance of Tysabri sales globally.
- Januvia/Janumet: Royalty Pharma has a royalty interest in Januvia/Janumet (sitagliptin), medications for type 2 diabetes. Competitors include other diabetes drugs such as those from Novo Nordisk (NVO) and Eli Lilly (LLY). Revenue and market share data are confidential, and Royalty Pharma's revenues are tied to the overall performance of these sales globally.
- Spinraza: Royalty Pharma holds a royalty interest in Spinraza, a therapy for Spinal Muscular Atrophy. Competitors include Novartis (NVS) and Roche (RHHBY) with their own SMA treatments. Revenue and market share data are confidential, and Royalty Pharma's revenues are tied to the overall performance of these sales globally.
Market Dynamics
Industry Overview
The pharmaceutical royalty market is characterized by high barriers to entry, specialized knowledge requirements, and long investment horizons. It is experiencing growth due to increasing R&D costs and the need for innovative financing solutions.
Positioning
Royalty Pharma is the dominant player in the pharmaceutical royalty market, distinguished by its scale, experience, and access to capital. Its competitive advantage lies in its ability to assess and manage the risks associated with acquiring royalties.
Total Addressable Market (TAM)
The pharmaceutical royalty market is estimated to be billions of dollars annually. Royalty Pharma is well-positioned to capture a significant share of this TAM due to its established market leadership and specialized investment strategy.
Upturn SWOT Analysis
Strengths
- Dominant market position
- Experienced management team
- Diversified portfolio of royalties
- Strong cash flow generation
- High barriers to entry
Weaknesses
- Concentration risk in key products
- Dependence on success of underlying drugs
- Exposure to regulatory and patent risks
- Complex financial instruments
- Limited control over development and marketing of underlying drugs
Opportunities
- Expanding into new therapeutic areas
- Acquiring royalties on emerging blockbuster drugs
- Co-funding clinical trials for promising new therapies
- Geographic expansion
- Increasing demand for alternative financing solutions in the pharmaceutical industry
Threats
- Patent expirations
- Generic competition
- Regulatory changes
- Clinical trial failures
- Increased competition from other royalty investors
Competitors and Market Share
Key Competitors
- DRI (DRIP)
Competitive Landscape
Royalty Pharma has a dominant position compared to DRI. It is larger, and it has more experience and access to capital.
Major Acquisitions
Biohaven Pharmaceutical Holding Company Ltd.
- Year: 2022
- Acquisition Price (USD millions): 1150
- Strategic Rationale: Acquisition of Biohaven's royalty on Nurtec ODT to diversify portfolio.
Growth Trajectory and Initiatives
Historical Growth: Royalty Pharma's growth has been driven by its acquisitions of royalties on blockbuster drugs and co-funding clinical trials.
Future Projections: Future growth is expected to be driven by continued royalty acquisitions and the success of its co-funded clinical trials. Analyst estimates vary depending on market conditions and acquisition activity.
Recent Initiatives: Recent initiatives include acquisitions of royalties on new drugs and expansion into new therapeutic areas.
Summary
Royalty Pharma is the dominant player in the pharmaceutical royalty market. The company has strong cash flow and experienced leadership. Patent expirations and regulatory changes represent potential risks to its portfolio. Successful acquisition and diversification strategies will drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Royalty Pharma Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Royalty Pharma Plc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 1993-03-25 | Founder, Chairman of the Board & CEO Mr. Pablo Gerardo Legorreta | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.royaltypharma.com |
Full time employees - | Website https://www.royaltypharma.com | ||
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.